Please try another search
For the three months ended 31 March 2022, AptaBio Therapeutics Inc revenues decreased 91% to W10.1M. Net loss decreased 18% to W2.6B. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects R & D Expense decrease of 52% to W907.5M (expense), Interest Income increase of 25% to W383.3M (income), Commission Paid decrease of 11% to W123.8M (expense).
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Dec 31, 2021 |
---|---|---|---|---|
Total Revenue | 289.21 | 8.39 | 26.27 | 12.46 |
Gross Profit | 39.72 | 8.39 | 12.96 | |
Operating Income | -6093.69 | -4213.64 | -6596.2 | -2950.62 |
Net Income | -8307.91 | -4169.46 | -6620.46 | -2341.37 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Dec 31, 2021 |
---|---|---|---|---|
Total Assets | 92519.12 | 100944.95 | 64910.6 | |
Total Liabilities | 38191.91 | 36889.11 | 3245.56 | |
Total Equity | 54327.21 | 64055.84 | 61665.04 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Dec 31, 2021 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -7958.34 | -8897.24 | ||
Cash From Investing Activities | -599.79 | 1133.09 | ||
Cash From Financing Activities | -35.11 | -375.68 | ||
Net Change in Cash | -8606.43 | -8119.74 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review